AEterna Zentaris appoints new president and CEO
This article was originally published in Scrip
AEterna Zentaris has appointed Professor Jurgen Engel as president and CEO, effective September 1st. Professor Engel is currently executive vice-president and chief scientific officer at the company, and as president will focus on the development of AEterna Zentaris's pipeline, particularly for the company's lead compound for prostatic hyperplasia, cetrorelix. Dr Engel succeeds Juergen Ernst, who has been acting as interim president and CEO since April, and who will now take the role of executive chairman, also effective September 1st.